ABSTRACT
TFPI is a multivalent, Kunitz-type proteinase inhibitor, which, due to alternative mRNA splicing, is transcribed in three isoforms: TFPIalpha, TFPIdelta, and glycosyl phosphatidyl inositol (GPI)-anchored TFPIbeta. The microvascular endothelium is thought to be the principal source of TFPI and TFPIalpha is the predominant isoform expressed in humans. TFPIalpha, apparently attached to the surface of the endothelium in an indirect GPI-anchor-dependent fashion, represents the greatest in vivo reservoir of TFPI. The Kunitz-2 domain of TFPI is responsible for factor Xa inhibition and the Kunitz-1 domain is responsible for factor Xa-dependent inhibition of the factor VIIa/tissue factor catalytic complex. The anticoagulant activity of TFPI in one-stage coagulation assays is due mainly to its inhibition of factor Xa through a process that is enhanced by protein S and dependent upon the Kunitz-3 and carboxyterminal domains of full-length TFPIalpha. Carboxyterminal truncated forms of TFPI as well as TFPIalpha in plasma, however, inhibit factor VIIa/tissue factor in two-stage assay systems. Studies in gene-disrupted mice demonstrate the physiological importance of TFPI.
INTRODUCTION
As early as 1922, Loeb suggested that serum contained a moiety that inhibits the procoagulant activity of tissue extracts (1, 2). Later, Thomas (3) and Schneider (4) independently demonstrated the in vivo correlate of this observation by showing that the incubation of tissue thromboplastin with serum prevented its lethal effect when infused into animals. Thomas (3) also noted that the inhibitory effect of serum required the presence of calcium ions, that the inhibitor appeared to bind to thromboplastin, and that the effect could be reversed by calcium ion chelators. The calcium ion requirement and reversibility of the thromboplastin inhibition were subsequently confirmed by in vitro coagulation assays (5-9). In 1957, Hjort (10) reported that the previously described serum inhibitor of thromboplastin recognized the factor VIIa-Ca 2+ -tissue factor complex, which he termed convertin, rather than factor VII (proconvertin) or thromboplastin alone. He ascribed the calcium dependence and reversibility of the inhibition by calcium chelation to the requirement for convertin formation and, using indirect means, suggested that the binding of the inhibitor to convertin was calcium ion-dependent as well. Figure 1 . Structure of the human TFPI Gene. The TFPI gene spans 90 kb and contains 10 exons (vertical boxes) and 9 introns that encode for three isoforms. Exons are labeled numerically (top), introns alphabetically (bottom). Translated exons encoding TFPIalpha are filled in blue. Alternatively spliced exons leading to the generation of TFPIdelta and TFPIbeta are filled in magenta and red, respectively. Exons 1 and 2 encode 5' untranslated (5'UT) sequences with alternative splicing resulting in the absence of exon 2 in some messages. Exon 3 encodes the signal peptide and amino terminal peptide (SP+NT). Exons 4, 6 and 9 encode Kunitz domains 1 (K1), 2 (K2) and 3 (K3), respectively and intervening peptide sequences that link the Kunitz domains are encoded by exons 5 (IP1) and 7 (IP2). A run-on of exon 6 into intron F (magenta) encodes the short TFPIdelta variant carboxyl terminus (deltaCT). The TFPIbeta carboxy-terminal peptide (betaCT) is encoded by exon 8 (red) and splicing of exon 7 to exon 8 occurs to generate the TFPIbeta message. In the TFPIalpha message exon 9 is directly spliced to exon 7 (K3) and to exon 10 (alphaCT), thereby encoding the Kunitz-3 and carboxyterminus of the TFPIalpha protein.
Nearly 25 years later, Carson reported that plasma lipoproteins inhibited the catalytic activity of the factor VIIa/tissue factor complex (11) and Dahl et al. showed that the anticonvertin activity of Hjort eluted in two highmolecular-weight peaks on gel filtration of plasma, consistent with an association with plasma lipoproteins (12). Subsequently, Morrison and Jesty (13) demonstrated that the activation of factor IX and factor X in plasma was incomplete following the addition of tissue factor and that this apparent inhibition of factor VIIa/tissue factor enzymatic activity was directly related to the presence of factor X or brief pretreatment of the plasma with factor Xa. Rapaport and colleagues (14) then confirmed that both factor X and an inhibitor present in the total lipoprotein fraction of plasma were required for this apparent inhibition of tissue factor-mediated coagulation. Additional studies corroborated the earlier work (15) (16) (17) (18) and went on to show that the inhibitor produced factor Xa-dependent feedback inhibition of the factor VIIa-tissue factor complex (19, 20) . The inhibitor was initially purified from the conditioned media of HepG2 (human hepatoma) cells (21) and subsequently its cDNA cloned (22) and the organization of its gene determined (23, 24) . This inhibitor has been called antithromboplastin, anticonvertin, the factor Xa-dependent factor VIIa-tissue factor inhibitor, tissue factor inhibitor, extrinsic pathway inhibitor, and lipoprotein-associated coagulation inhibitor. In 1991, a subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis settled on the currently used name, tissue factor pathway inhibitor (TFPI).
Although TFPI may play additional roles in innate immunity, microbial defense, inflammation, angiogenesis, lipid metabolism, and cellular signaling, proliferation, migration, and apoptosis, the focus of this review is its regulation of coagulation.
ISOFORMS
The TFPI gene spans approximately 90 kb on the long arm of chromosome 2 (q32) and contains ten exons and nine introns (Figure 1 ) [(23, 24) , GenBank: NC_000002.11]. All the splice junctions between exons are of the same type (type 1), which suggests that the TFPI gene was assembled during evolution through a process of gene duplication and exon shuffling.
Three alternatively transcribed isoforms of TFPI have been identified. TFPIalpha (GenBank NM_006287.4) is the originally isolated form of TFPI (Figure 2 ). Exons 1 and 2 encode 5' untranslated regions and due to alternative splicing exon 2 is absent in some messages. Exon 3 encodes the signal peptide, which is removed during processing of the protein, and the aminoterminus of the mature TFPI. The TFPIalpha molecule contains three tandem Kunitz-type proteinase inhibitor domains that are encoded by separate exons (4, 6, and 9) and intervening peptides between Kunitz domains that are encoded by exons 5 and 7. The carboxyterminus of the TFPIalpha protein and an extensive 3' untranslated region are encoded by exon 10.
An alternatively spliced form of TFPI mRNA, called TFPIbeta was initially detected in mice (25) .
In human TFPIbeta mRNA (GenBank NM_001032281.2), exon 8, which contains a stop codon and polyadenylation signal, is used in place of exons 9 and 10 and this leads to the production of an alternative carboxyterminus inserted at residue 182 that directs the attachment of a glycosyl phosphatidyl inositol (GPI) anchor ( Figure  3 ). . Positively charged amino acids are shown in red, negatively charge amino acids in blue and neutral amino acids in white (histidine residues are considered uncharged). The Kunitz domains are labeled and the basic P 1 residues at the active site cleft for each domain is shown in black.
N-linked glycosylation sites are denoted at N117 and N167 by and O-linked glycosylation sites are denoted at T14, S174 and T175 by . Partial phosphorylation at Ser2 is also shown . The sites of introns in the TFPI gene are labeled with dotted lines and capital letters.
An additional variant form of hTFPI mRNA (TFPIdelta) is listed in the GenBank (human: AB209866.1; chimpanzee: XM_001161803.1) and is consistent with intron F retention (Figure 4 ). Within the intron are a downstream stop codon and a polyadenylation signal. This message generates a truncated form of TFPI with the insertion of a new 12 amino acid C-terminus at residue 151 following the Kunitz-2 domain of TFPIalpha.
In human umbilical vein endothelial cells (HUVECs) and endothelial-like cell lines (EAhy926, ECV304) the ratio of TFPIalpha/TFPIbeta mRNA varies between 5 and 10 (26). The TFPIalpha protein has been purified from the conditioned media of HepG2 cells and plasma (21, 27, 28) , but TFPIbeta protein has thus far only been identified indirectly in ECV304 cells (a bladder cancer cell line with some endothelial characteristics) (26, 29, 30) and reportedly is not produced by EAhy926 cells (31) . Tissue northern blot analysis shows predominant TFPIdelta mRNA in the liver in contrast to the expression of TFPIalpha mRNA, which is highest in vascular tissues like the lung and placenta ( Figure 5 ). Whether the northern result, however, represents significant expression of TFPIdelta, simply a splicing error that occurs more commonly in the liver, or a mechanism for regulating TFPI expression through unproductive splicing and translation (RUST) and nonsense-mediated mRNA decay (NMD) (32) is not clear and detection of the TFPIdelta protein has not yet been reported.
STRUCTURE
The primary structure of TFPIalpha is unique (Figure 2) (22) . After a 24 or 28 amino acid signal peptide, the mature protein has 276 residues (32 kDa) and contains an acidic aminoterminal region followed by three tandem Kunitz-type protease inhibitory domains and a basic carboxyterminal region. and partially to Thr 14 and Ser 174 (33). Interestingly, the sugar chains linked to Asn 117 appear to contain a sialyl Lewis X structure. The oligosaccharides in TFPI expressed by certain cells in vitro (e.g. rabbit endothelial cells, HEK293 cells) are sulfated (34-36), but sulfated sugar chains were not detected in TFPIalpha isolated from human plasma (33). Ser 2 is partially phosphorylated in the TFPI expressed by some cells in tissue culture, likely through the action of casein kinase II (37), and it has been estimated that ~15% of TFPIalpha isolated from plasma is phosphorylated (33). These post-translational modifications do not appear to significantly affect the known proteinase inhibitory properties of TFPIalpha (38) .
TFPIbeta lacks the Kunitz-3 and basic carboxyterminal domains of TFPIalpha and in their place contains a 42 amino acid carboxyterminal sequence inserted following residue 181 of TFPIalpha (Figure 3 ). This new carboxyterminal sequence is predicted to direct the proteolytic cleavage of the peptide following N193 with the attachment of a GPI anchor. The protein mass of TFPIbeta is less than that of TFPIalpha (22 versus 32 kDa), but it migrates on SDS-PAGE at the same apparent molecular weight as TFPIalpha (43 kDa) due to greater sialylation of its O-linked carbohydrate (30) .
Kunitz-type inhibitors appear to act by the standard mechanism (39) in which the inhibitor feigns to be a good substrate, but, after the enzyme binds, the subsequent cleavage between the P 1 and P 1 ' amino acid residues at the active site cleft of the inhibitor occurs slowly or not at all. The P 1 residue is an important determinant of the specificity of these inhibitors, and alterations of the residue in the P 1 position can profoundly affect their inhibitory activity. In kinetic terms, Kunitz-type inhibitors typically produce slow, tight-binding, competitive, and reversible enzyme inhibition
In the reaction, the Kunitz-type inhibitor forms an initial "encounter" complex (EI) with the enzyme and this complex then "slowly" isomerizes to a much tighter form (EI*). "Slow" implies that the final degree of inhibition does not occur immediately, and "tight-binding" means that inhibition occurs at a concentration of the inhibitor that is near to that of the enzyme.
Experiments in which the P 1 residue of each Kunitz domain in TFPIalpha was individually altered have shown that the Kunitz-2 domain of TFPI mediates factor Xa binding and inhibition, whereas the Kunitz-1 domain is necessary for the inhibition of factor VIIa in the factor VIIa-tissue factor complex (40) . Alteration of the P 1 residue in the third Kunitz domain does not affect either of these functions of TFPIalpha. Studies examining the inhibitory properties of the isolated Kunitz domains of TFPI have reached the same conclusions and have shown that the Kunitz-3 domain lacks proteinase inhibitory activity (41) . The placement of serine at residue 220 in Kunitz-3 (residue 36 in aprotinin numbering), instead of the conserved glycine present in Kunitz domains with proteinase inhibitory activity, likely induces a conformational change that restricts the entry of the Kunitz domain into the substrate-binding pocket of serine enzymes (41, 42) . TFPIalpha also inhibits trypsin and chymotrypsin reasonably well and inhibits cathepsin G, plasmin, and activated protein C poorly (43, 44); the physiologic significance of these inhibitory reactions, however, is doubtful.
DISTRIBUTION
The microvascular endothelium is thought to be the major source of TFPI in vivo. Northern blot analysis of tissues shows the highest TFPI mRNA levels in the placenta and lung and the lowest in the brain (45). Studies of normal tissues have detected TFPI protein in the endothelium of the microvasculature, smooth muscle cells, monocytes/macrophages, megakaryocytes/platelets, mesangial cells, fibroblasts, microglia, cardiomyocytes, and mesothelial cells (46-55).
Plasma TFPI
The mean plasma TFPI concentration in normal individuals is ~70 ng/mL (1.6 nM) [e.g. (56) . Distribution of TFPI. In plasma, carboxyterminal truncated forms of TFPI are bound to lipoproteins and comprise ~80% of circulating TFPI (blue). Whether these forms represent extensively truncated forms of TFPIalpha, TFPIbeta or TFPIdelta has not been determined. "Free" forms of TFPI (~20%) contain the Kunitz-3 domain and include carboxyterminal truncated forms of TFPIalpha (~10%) (yellow) and full-length TFPIalpha (~10%) (green). Following heparin treatment in vivo, the level of total TFPI in plasma increases 1.5-3.0-fold and the released TFPI is full-length TFPIalpha. Platelets carry a level of full-length TFPIalpha that is equivalent to that present in plasma. At sites where platelets aggregrate, the contribution of platelets to the local concentration of full-length TFPIalpha could exceed the level of full-length TFPIalpha in plasma by >30-fold. Based on studies of cultured endothelial cells, the quantity of surface TFPI released by PIPLC greatly exceeds (>5-fold) that released by heparin. The PIPLC-releasable TFPI appears predominantly to be full-length TFPIalpha; PIPLC-induced release of TFPIbeta has not yet been documented in human endothelial cells. levels because LDL is a major carrier; plasma concentrations increase with diet-induced hypercholesterolemia in monkeys and decrease in response to statin therapy in individuals with familial hypercholesterolemia (58-61). Individuals with abetalipoproteinemia lack LDL and have low levels (~25%) of TFPI in plasma (62), but do not have a prothrombotic phenotype, suggesting that non-lipoprotein-associated forms of TFPI in plasma and/or TFPI at other endogenous locales are physiologically important.
Predominant forms of TFPI in plasma have molecular weights of 34 and 41 kDa, and less abundant forms of higher molecular mass are also present (27, 63) . The size heterogeneity of plasma TFPI reflects, in part, the carboxyterminal truncation of the TFPIalpha molecule and the formation of mixed disulfide complexes with apolipoprotein-AII and potentially other proteins (63) . The major form of TFPI bound to LDL has a molecular weight of 34 kDa and lacks the distal portion of full-length TFPIalpha, including at least a large portion of the Kunitz-3 domain. The 41 kDa form of TFPI that circulates with HDL appears to represent a similar carboxy-truncated form of TFPI that is disulfide-linked to monomeric apolipoprotein-AII. Whether the lipoprotein-associated TFPIs are extensively carboxytruncated forms of TFPIalpha or modified forms TFPIbeta or TFPIdelta has not been established and the mechanism underlying the association of 34 kDa TFPI with LDL has not been determined.
TFPI antigen assays utilizing antibodies against the Kunitz-3 domain of TFPIalpha do not recognize lipoproteinbound TFPI and measure "free" TFPI, ~20% of total plasma TFPI (64, 65) ( Figure 6 ). These assays detect forms of TFPIalpha with limited carboxyterminal truncation produced by an as yet unidentified proteinase(s) and full-length TFPIalpha, which probably represents ~50% of the "free" TFPI or ~10% of total plasma TFPI. Whether TFPIbeta, enzymatically released or shed in membrane vesicles from cell surfaces, circulates in human plasma is not known.
In vitro experiments have shown that TFPIalpha can be proteolytically degraded by a variety of proteinases, including thrombin, plasmin, neutrophil elastase, cathepsin G, factor Xa (when at molar excess over TFPIalpha), cellderived matrix metalloproteinases, and bacterial omptins (55, [66] [67] [68] [69] [70] [71] [72] . Plasmin-mediated degradation of TFPI in plasma and on the monocyte surface has been demonstrated in patients following thrombolytic therapy and likely on the cells of the lung in septic baboons (73, 74) . The degradation of TFPI by neutrophil proteinases, especially elastase, has been shown to enhance microvascular coagulation thereby limiting the tissue dissemination of bacterial pathogens, but to also increase large vessel thrombosis (75) . The cleavage of TFPI by neutrophil elastase is facilitated by neutrophil-derived externalized nucleosomes, which form neutrophil extracellular traps (NETs) that serve to co-localize neutrophil elastase and TFPI.
Plasma concentrations of "free" and full-length TFPIalpha are reduced in the plasmas of patients with factor V deficiency, protein S deficiency, and perhaps factor VIII deficiency (76) (77) (78) (79) . Apparent binding interactions between full-length TFPIalpha and factor V and protein S have been demonstrated in plasma and by surface plasmon resonance in purified systems (76, 77, 80, 81) . Whether these interactions affect the expression, proteolytic degradation, or clearance of TFPIalpha remains to be determined.
Platelet TFPI
TFPIalpha is expressed by megakaryocytes, stored in platelets at a site separate from alpha granules, and released in response to thrombin and other agonists (82, 83). In "coated" platelets produced by dual agonist stimulation (e.g. thrombin/collagen, thrombin/convulxin), a proportion of the released TFPIalpha remains bound and functional at the activated platelet surface (83) . Similar to other ligands (e.g. factor V, fibrinogen, von Willebrand factor) detected on the surface of coated platelets, transglutaminase inhibitors prevent this retention of surface TFPIalpha (83).
The full-length TFPIalpha carried in platelets is 8-10% of the total TFPI in blood (82, 83), which is comparable to the quantity of soluble full-length TFPIalpha in plasma ( Figure 6 ). Thus, it is likely that platelets are a major source of full-length TFPIalpha, the most anticoagulantly active form of TFPI (see below), at local sites of coagulation where platelets aggregate.
The total TFPI concentration in the blood exuding from bleeding time wounds increases 3.5-fold by the time the bleeding stops (~9 min.) (82). If this increase is due to the release of TFPIalpha from stimulated platelets this would represent a >30-fold increase in local concentrations of full-length TFPIalpha. On the other hand, polyphosphates released from the dense granules of stimulated platelets modestly reduce the anticoagulant effects of TFPIalpha in plasma coagulation assays, apparently in part through their enhancement of factor V activation (84, 85) .
Cell-associated TFPI
Several reports have documented the low affinity, heparin-inhibitable binding of TFPIalpha to cells potentially mediated by surface proteoglycans, the internalization and degradation of TFPIalpha through the action of the LDLreceptor-related protein (LRP), and the rapid clearance of TFPIalpha in animals [e.g. (86) (87) (88) (89) (90) (91) (92) (93) (94) (95) ]. These studies used recombinant TFPIalpha (rTFPIalpha) that lacked the posttranslational modifications found in mammalian TFPIalpha. In contrast, the rTFPIalpha produced by at least one mammalian cell line (mouse C127) does not bind to cells or interact with LRP in the same fashion as E.coli rTFPIalpha and is cleared from plasma at a 10-fold slower rate (96) . Therefore, the studies that used non-mammalian derived TFPI should probably be viewed with considerable caution.
Cell Surface TFPI
A substantial fraction of the TFPI produced by endothelial cells remains at the cell surface, associates with caveolae, and is released by phosphatidylinositol-specific phospholipase C (PIPLC) (Figures 6 and 7) (26, (29) (30) (31) (97) (98) (99) (100) . These are properties of GPI-anchored proteins. The predominant form of TFPI released from the surface of endothelial cells by PIPLC is TFPIalpha. The amino acid sequence of TFPIalpha, however, does not contain the appropriate motifs to direct the canonical carboxyterminal cleavage and attachment of a GPI anchor and the TFPI released from the surface of endothelial cells by PIPLC contains the carboxyterminus of full-length TFPIalpha (31).
The cell surface binding of TFPIalpha therefore appears to involve its interaction with a separate, as yet unidentified, GPI-anchored co-receptor(s) (26, 29, (97) (98) (99) (100) that may control its cellular trafficking and surface expression (31) . Very little rTFPIalpha is detected on the surface of transfected Chinese hamster ovary (CHO) cells (26, 29) and human embryonic kidney (HEK293) cells (101) suggesting that: 1) these cells do not express the co-receptor; 2) these cells express a form of TFPIalpha lacking a post-translational modification that is required for co-receptor binding; or 3) the interaction between TFPIalpha and the co-receptor demonstrates species-specificity in the case of CHO cells. In transfected cells that do display PIPLC-releasable rTFPIalpha (e.g. mouse C127 cells), the surface binding requires the Kunitz-3 and carboxyterminal domains of TFPIalpha and a single mutation of the P 1 residue in Kunitz-3 (R199L) substantially reduces the cell surface localization of rTFPIalpha (29) .
Treatment of cultured endothelial cells with heparin or heparitinase does not perceptibly reduce surface TFPI (26, 29, 98) . PIPLC treatment releases ~80% of the surface TFPI and the remaining TFPI can then be removed by subsequent heparin treatment (26, 29, 31) . This suggests that the interaction of TFPI with the cell surface is complex and may involve more than a single entity. The surface distribution of exogenously offered E. coli rTFPIalpha does not mirror that of endogenously expressed TFPI (99) and, although the E. coli rTFPIalpha is a potent inhibitor cell surface factor VIIa/tissue factor/factor Xa activity, it inhibits factor VIIa/tissue factor/factor Xa-mediated signaling through protease-activated receptors (PARs) poorly compared to mammalian cell surface expressed TFPIalpha (102) . In endothelial cells induced to produce tissue factor, the GPIanchored TFPI serves to redistribute factor VIIa/tissue factor to caveolae in a factor Xa-dependent manner (97, 99) . GPIanchorage, however, may not be a requirement for factor VIIa/tissue factor inhibition by cell surface TFPIalpha as chimeric forms of rTFPIalpha anchored by a GPI-anchor or a transmembrane domain produce equivalent levels of factor VIIa/tissue factor inhibition (103).
Whether TFPI is attached to the surface of other TFPI expressing cells (e.g. vascular smooth muscle cells, monocytes) in the same manner as in endothelial cells remains to be determined. Studies of the rTFPIbeta isoform of TFPI in transfected cells demonstrates that it possesses an intrinsic GPI anchor (26, 29, 30) , but direct evidence for the production of the TFPIbeta protein by human endothelial cells is currently lacking, despite the presence of TFPIbeta mRNA in these cells.
Releasable TFPI
Heparin, thrombin, and shear increase the expression and release of TFPI from cells in culture (26, 29, (104) (105) (106) (107) (108) . The release of TFPI induced acutely by these agonists appears to involve the redistribution of TFPI from stores located near the plasma membrane (perhaps caveolae) to the cell surface with the subsequent release into the media The factor VIIa/tissue factor (TF) catalytic complex on a phospholipid surface activates factor X and factor IX (top). TFPI (center) binds to the transient tertiary factor VIIa/tissue factor/factor Xa complex (left) produced during the activation of factor X, forming a quaternary factor VIIa/tissue factor/factor Xa/TFPI inhibitory complex (bottom) in which the Kunitz-1 and Kunitz-2 domains of TFPI bind and inhibit factor VIIa and factor Xa, respectively. On the right, factor Xa, protein S and TFPI are shown forming an inhibitory complex at a phospholipid surface in which the Kunitz-2 domain binds and inhibits factor Xa and the Kunitz-3 and carboxyterminal domains of TFPIalpha are required for its interaction with protein S. Direct inhibition of factor Xa by TFPI and an alternative two-step pathway for factor VIIa/tissue factor inhibition in which a factor Xa/TFPI complex binds to factor VIIa/tissue factor producing the final quaternary inhibitory complex are not shown. Also not depicted are the factor VIIa/tissue factor and factor Xa inhibition produced by cell membrane-bound forms of TFPI. The Kunitz-1, Kunitz-2 and Kunitz-3 domains of TFPI are labeled K1, K2 and K3, respectively. of a portion of the total cellular TFPI. During this process, the TFPI available at the surface of the cells remains unchanged or increases.
The parenteral administration of heparin and low-molecular-weight heparin, but not the heparin pentasaccharide (fondaparinux), rapidly increases the circulating levels of total TFPI in plasma 1.5-3 fold (Figure 6 ) (62, (109) (110) (111) . Repeated doses of unfractionated heparin, but not low-molecular-weight heparin, exhaust the TFPI releaseresponse (112) (113) (114) . The form of TFPI that is released appears to be full-length TFPIalpha (28) and its source is presumed to be the endothelium.
The in vitro experiments discussed above show that: 1) Heparin treatment alone releases only a small fraction of cellular TFPI; 2) PIPLC treatment alone releases ~80% of cell surface TFPI and the remainder is released by subsequent heparin treatment; and 3) prior PIPLC treatment dramatically increases the amount of TFPI released by heparin (26, 29, 100) . The mechanism(s) underlying these phenomena has not been elucidated, but appears to be more complicated than simply the "stripping" of TFPI from proteoglycan binding sites on the surface of the endothelium.
REGULATION OF COAGULATION
TFPI limits coagulation through both the inhibition of factor Xa, a process recently shown to be enhanced by protein S, and factor Xa-dependent feedback inhibition of factor VIIa/tissue factor. These properties of TFPI led to a reformulation of the coagulation cascade (19, 20, 115, 116) in which factor VIIa/tissue factor activation of factor IX and factor X is responsible for the initiation of coagulation, but subsequent amplification of the clotting process through the action of the factor IXa/factor VIIIa complex, a much more potent activator of factor X than factor VIIa/tissue factor (117), is required for hemostasis. The TFPI-mediated inhibition of factor Xa generation by factor VIIa/tissue factor, the inability to rapidly generate additional factor Xa through the action of factor IXa/factor VIIIa to overcome TFPImediated factor Xa inhibition, and the consequent dramatic reduction in thrombin generation helps explain the bleeding seen in individuals with hemophilia.
Factor Xa Inhibition
The Kunitz-2 domain of TFPI is responsible for the direct inhibition of factor Xa (19, 40) (Figure 8 ). The factor Xa-TFPI complex can form in the absence of calcium ions and is reversed by treatment with sodium dodecyl sulfate or high concentrations of the serine protease inhibitor benzamidine, which binds to the active site of factor Xa (19, 118) . Other parts of the TFPI molecule besides the Kunitz-2 domain, however, are involved in its interaction with factor Xa. The carboxyterminal domain of TFPIalpha is required for rapid, efficient factor Xa inhibition (25, 41, (119) (120) (121) (122) (123) and cleavage of TFPI between Kunitz domains 1 and 2 (e.g. produced by neutrophil elastase) dramatically reduces the ability of TFPI to inhibit factor Xa (69) . The inhibition of factor Xa by TFPI in the presence of physiologic calcium ion concentrations is enhanced by procoagulant phospholipids (122). The basic carboxyterminal region of the TFPIalpha molecule is important for this effect (119, 120) and presumably permits the simultaneous interaction of factor Xa and TFPIalpha with the phospholipid surface. Although the TFPIbeta isoform lacks the carboxyterminus of TFPIalpha, its relatively slow inhibition of factor Xa in soluble phase (25) might be significantly enhanced when it is bound to phospholipid surfaces via its GPI-anchor (124) .
Protein S enhances the inhibition of factor Xa by TFPIalpha in the presence of phospholipids and calcium ions by increasing the affinity of the initial encounter complex between factor Xa and TFPIalpha 10-fold, to near the concentration of full-length TFPIalpha in plasma (125) . This effect requires the Kunitz-3 and carboxyterminal domains of TFPIalpha, is reduced by a mutation at the P 1 site of the Kunitz-3 (R199L) in TFPIalpha, and appears to involve at least in part a direct interaction of protein S with the Kunitz-3 domain (81, 125). The TFPIalpha structures required for the protein S-dependent enhancement of factor Xa inhibition mimic those required for TFPIalpha binding at the surface of endothelial cells, suggesting that protein S, which is also expressed by endothelial cells, may be involved in that interaction as well. As protein S binds factor Xa in a calcium ion and phospholipid-dependent fashion (126), the most straightforward explanation for the potentiating effect of protein S on factor Xa inhibition by TFPIalpha is that an association between protein S and TFPIalpha serves to increase TFPIalpha's interactions with phospholipids and with factor Xa at phospholipid surfaces.
In mixtures containing prothrombin, factor Xa, factor V, phospholipids and calcium ions, TFPIalpha, with or without protein S, dramatically delays the initiation and reduces the ultimate rate of thrombin generation (81, 122, 127). In contrast, in similar mixtures containing factor Va, rather than factor V, TFPIalpha with or without protein S inhibits factor Xa activity only in the absence of prothrombin. Therefore the anti-factor Xa action of TFPIalpha must precede the activation of factor V and the formation of the prothrombinase complex or occur at sites where prothrombin has been consumed.
Heparin and other polyanions accelerate TFPIalpha-mediated inhibition of factor Xa (120). The heparin dose-response for this effect exhibits an optimum, which suggests that the polyanion forms a template to which factor Xa and TFPIalpha simultaneously bind (120, 122) . Basic residues within the Kunitz-3 and carboxyterminal domains of TFPIalpha are required for optimal heparin binding, and progressive carboxyterminal truncation of the TFPI molecule produces proteins with decreasing affinity for heparin (120, 128) . Rather than a specific binding epitope, charge density on the glycosaminoglycan appears to be most important for TFPIalpha binding (129).
Factor VIIa/Tissue Factor Inhibition
Factor Xa-dependent inhibition of factor VIIa/tissue factor requires the Kunitz-1 domain of TFPI and involves the formation of a quaternary factor Xa-TFPI-factor VIIa/tissue factor complex (Figure 8) (19, 20) . The final quaternary complex could be produced in a two-step process in which TFPI first binds factor Xa and then the factor Xa-TFPI complex binds and inhibits factor VIIa/tissue factor. That this two-step pathway can occur has been documented in vitro. Kinetic studies, however, strongly suggest an alternative pathway in which TFPI interacts with the tertiary complex of factor VIIa/tissue factor/factor Xa, which forms transiently during the activation of factor X and from which the product factor Xa dissociates relatively slowly (130) . As a result, factor VIIa/tissue factor inhibition is extremely rapid and the concentration of active factor Xa that escapes regulation depends linearly on the quantity of available of tissue factor. The fact that protein S substantially enhances the formation of the factor Xa-TFPI complex, but does not increase the inhibition of factor VIIa/tissue factor by TFPI is consistent with this alternative pathway (131) . The Gla domain of factor Xa and Lys 165 -Lys 166 of tissue factor, which are structures required for the optimal recognition of factor X by factor VIIa/tissue factor, are also important for the inhibition of factor VIIa/tissue factor by factor Xa-TFPI (19, 132, 133) . Studies of the effects of heparin on factor Xa-dependent factor VIIa/tissue factor inhibition by TFPI have produced conflicting results (123, 134) .
Full-length TFPIalpha inhibits factor Xa much faster than carboxyterminal truncated forms (25, 41, 119, 120) . In contrast, full-length and carboxyterminal truncated forms of TFPIalpha appear to inhibit factor X activation by factor VIIa/tissue factor at comparable rates (134) (135) (136) . A detailed kinetic analysis of these reactions, however, has not been performed. The ultimate affinity of the quaternary inhibitory complex formed with full-length TFPIalpha is greater than that of complexes formed with truncated TFPI as the latter inhibitory complexes dissociate more rapidly (135, 136) .
The requirement of factor Xa for the inhibition of factor VIIa/tissue factor by TFPI is not absolute and high concentrations of TFPI will inhibit factor VIIa/tissue factor in the absence of factor Xa (41, 137, 138) . This factor Xa-independent inhibition of factor VIIa/tissue factor by TFPI, however, is of uncertain physiologic relevance.
Anticoagulant Activity
The exogenous addition of non-physiologic concentrations of TFPIalpha to plasma inhibits the coagulation induced by factor Xa, the X-coagulant protein from Russell's viper venom, and tissue factor to a similar extent (119) , implying that the anticoagulant activity of TFPIalpha in these one-stage assays is due to its inhibition of factor Xa. An optimal effect requires the presence of protein S and is dependent on the Kunitz-3 and carboxyterminal domains of TFPIalpha (81, 119).
In plasma containing physiologic concentrations of full-length TFPIalpha (~0.2 nM), a similar effect of protein S and TFPI on thrombin generation can be demonstrated, but only at low concentrations of tissue factor (<14 ρM) or factor Xa (250 ρM) (139) . At higher concentrations of tissue factor, the rate and extent of factor Xa generation produced by factor IXa/factor VIIIa as well as factor VIIa/tissue factor is presumably sufficient to overwhelm the factor Xa inhibition mediated through TFPIalpha and protein S.
When the coagulation response to higher concentrations of tissue factor is limited by activation of the protein C pathway [e.g. addition of activated protein C (APC) or thrombomodulin to plasma], the effect of protein S/TFPI inhibition of factor Xa is again apparent (139, 140) . Indeed, the combination of the actions of APC and TFPIalpha, enhanced by their mutual cofactor protein S, serves to synergistically limit coagulation.
The effect of factor VIIa/tissue factor inhibition by TFPI on thrombin generation may be identifiable when low levels of tissue factor (1.5 ρM) are used to induce coagulation in plasma [ figure 1 and table 1 in (141) ]. In these experiments, the increase in peak thrombin generation produced by the addition of anti-TFPI antibodies to the plasma was considerably greater than that produced by the addition of anti-protein S antibodies. The difference in the response to anti-TFPI and anti-protein S antibodies could be due to the inhibition of factor VIIa/tissue factor by TFPI and/or the protein S-independent inhibition of factor Xa by TFPI. At higher concentrations of tissue factor, however, the inhibition of factor VIIa/tissue factor by TFPI is difficult to detect due to the rapid onset of the amplification phase of coagulation in which factor IXa/factor VIIIa are responsible for producing the vast majority of factor Xa.
While the full-length form of TFPIalpha is required for optimal factor Xa inhibition and the anticoagulant effect of TFPI in one stage coagulation assays (81, 119, 142) the factor VIIa/tissue factor inhibition produced by the carboxyterminal truncated forms of TFPI, present at ~10-fold higher concentrations than full-length TFPIalpha in plasma, is demonstrable in two stage assay systems (142, 143) . Though it seems likely that the attachment of carboxyterminal truncated forms of TFPI to large lipoprotein particles in plasma could hinder the recognition of cellular factor VIIa/tissue factor, this has not been directly tested.
The Cell-Surface Reservoir of TFPI
The amount of TFPI circulating in plasma represents only a small fraction of the total TFPI that is readily available. Heparin treatment in vivo induces the release of full-length TFPIalpha, raising levels of total TFPI in plasma 1.5-3-fold (28, 62, 109, 110) and the level of fulllength TFPIalpha >20-fold.
PIPLC treatment, however, releases much more TFPIalpha than heparin treatment from endothelial cells in culture (5-fold) (26, 100) and from placental tissue (>10-fold) (Figure 6 ) (100). Therefore, the major repository of TFPI is the indirectly GPI-anchored TFPIalpha on the surface of the endothelium and potentially other cells.
Why the majority of TFPI in vivo should be sequestered on the endothelial surface is not clear. Although a myriad of agonists has been shown to induce tissue factor production by endothelial cells in cell culture, the detection of endothelial tissue factor expression in vivo has been technically difficult and controversial. In part this could be due to the likely low levels of tissue factor that endothelial cells may produce, the specificity and potency of anti-tissue factor antibodies, and the problem of differentiating tissue factor intrinsically produced by endothelial cells from tissue factor that endothelial cells may corral from other cells or circulating microparticles.
Nevertheless, the apparent expression of tissue factor by vascular endothelium in vivo has been observed in a number of pathological states (144) (145) (146) (147) (148) (149) (150) (151) (152) (153) (154) (155) . Since the production of even low levels of tissue factor by the endothelium could be deleterious, the important function of endothelial cell-associated TFPI may be to control the procoagulant and cell signaling (102) actions mediated by tissue factor induced in endothelial cells regularly by less severe stimuli (156) .
IN MICE
Similar to humans, mice use alternative mRNA splicing to produce isoforms of TFPI. Messages for mTFPIalpha and mTFPIbeta are constructed in the same fashion as their human counterparts and recombinant mTFPIbeta is GPI-anchored when expressed in CHO cells. An additional isoform called mTFPIgamma, however, is present in the mouse, but not in humans nor apparently other species. For mTFPIgamma an exon downstream of that used to produce mTFPIbeta is inserted at the same splice acceptor site and encodes a different 18 amino acid carboxyterminus (157) . Whether mTFPIgamma protein is produced in the mouse is not clear.
In contrast to humans in whom TFPIalpha is the major protein form of TFPI generated, in the mouse TFPIbeta predominates. mTFPIalpha is present in mouse embryos and in the placenta and platelets of adult mice, but mTFPIalpha is not detectable in the other tissues of the adult mouse despite the fact that mTFPIalpha mRNA levels greatly exceed those of mTFPIbeta and mTFPIgamma in the tissues (83, 157, 158) . The basis for this discrepancy between mTFPIalpha mRNA and protein expression is unknown. The form of mTFPI in mouse plasma is mTFPIbeta (158) , which circulates at a level that is >20-fold the level of TFPI in human plasma and is not perceptibly increased following heparin treatment [Broze, unpublished data] .
A small quantity of mTFPIalpha, however, may be detectable in mouse plasma after heparin treatment (158) .
The genetic manipulations used in the production of the initial TFPI gene-disrupted mice led to deletion of the exon encoding the Kunitz-1 domain of mTFPI.
Due to alternative mRNA splicing, however, these TFPI knock-out mice continue to express a form of mTFPI lacking the Kunitz-1 domain at ~40% the normal level (159) . The loss of the Kunitz-1 domain prevents factor VIIa/tissue factor inhibition and likely also substantially reduces the factor Xa inhibition produced by the altered mTFPI ∆Κ protein (69) . Other potential functions of the remainder of the mTFPIalpha molecule, however, may remain intact in mTFPI ∆Κ (160) (161) (162) (163) (164) . TFPI Κ knock-out mice die intrautero of intravascular coagulation and a consumptive coagulopathy (159) and can be rescued by concomitant factor VII (165) or tissue factor (166) deficiency, confirming the critical role TFPI plays in regulating factor VIIa/tissue factor activity.
Heterozygous mTFPI Κ deficiency does not produce an obvious phenotype, but dramatically increases the prothrombotic phenotype of mice with factor V Leiden or thrombomodulin deficiency (167, 168) . In the murine apolipoprotein E (apoE) deficient model of atherosclerosis, heterozygous mTFPI Κ deficiency modestly increases the atherosclerotic burden in carotid and iliac arteries and reduces the Rose Bengal/laser light-induced occlusion time in atherosclerotic carotid arteries (169). Heterozygous mTFPI Κ deficiency also increases neointimal proliferation in the murine model of flow cessation-induced vascular remodeling (170). On the other hand, over expression of mTFPIalpha (the isoform only present in the platelets of adult mice) in vascular smooth muscle cells limits ferric chloride induced carotid artery occlusion (171) , reduces the smooth muscle cell proliferation and pulmonary vascular remodeling induced by chronic hypoxia (172) , and unexpectedly lowers plasma cholesterol levels and atherosclerotic plaque development in the apoE knockout model of atherosclerosis (173) .
Using a Cre-lox strategy, White and colleagues have shown that the deletion of mTFPI K1 in endothelial and hematopoietic cells reduces TFPI activity in plasma by 70% and increases ferric chloride-induced carotid artery thrombosis, but does not affect embryonic development (174) .
The results of bone marrow transplantation experiments suggest that the endothelium and bone marrow derived cells are responsible for ~50% and ~20% of the mTFPIbeta circulating in mouse plasma, respectively. The source of the remaining TFPIbeta in mouse plasma was not identified, but might be vascular smooth muscle cells or cardiomyocytes. Whether the demonstrated enhanced arterial thrombosis is due to simply a 70% reduction in plasma TFPI activity or to the tissue specific loss of TFPI activity in endothelial cells or hematopoietic cells cannot be discerned from these studies. The potential contribution of platelets, which are the major reservoir of mTFPIalpha in the mouse, might be of particular interest in this regard.
PERSPECTIVE
Since the rediscovery of TFPI, many of the mechanisms underlying its regulation of coagulation have been defined. That there is more to learn is exemplified by the only recently demonstrated co-factor role played by protein S in the inhibition of factor Xa by TFPIalpha. Moreover, important questions concerning TFPI physiology remain: At what levels are TFPIbeta and TFPIdelta expressed in humans; do the TFPI isoforms perform specific functions at specific locations; what is the form of TFPI circulating with lipoproteins in plasma and what is the mechanism for this association; which enzyme(s) is responsible for the carboxyterminal truncation of the plasma forms of TFPI; what is the relevance of potential interactions between TFPI and factor V and protein S in plasma; how is TFPIalpha bound at cell surfaces and the identity of its apparent GPI-anchored coreceptor; and what are the important physiological functions of this large reservoir of cell surface TFPI. The potential roles of TFPI in innate immunity, angiogenesis, and cellular functions that are not addressed in this review clearly also deserve attention. Studies in mice have demonstrated beyond doubt the critical importance of the regulation of tissue factormediated coagulation by TFPI. The substantial differences in TFPI physiology between mice and humans, however, need to be carefully considered before translating results in mouse models to the human situation.
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